Heska Stock Forecast, Price & News

+8.59 (+3.38 %)
(As of 08/4/2021 01:44 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume657 shs
Average Volume36,061 shs
Market Capitalization$2.74 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HSKA News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

Heska logo

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Additionally, the company provides a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.03 out of 5 stars

Medical Sector

537th out of 1,309 stocks

Diagnostic Substances Industry

5th out of 25 stocks

Analyst Opinion: 1.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Heska (NASDAQ:HSKA) Frequently Asked Questions

Is Heska a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Heska stock.
View analyst ratings for Heska
or view top-rated stocks.

What stocks does MarketBeat like better than Heska?

Wall Street analysts have given Heska a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Heska wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Heska?

Heska saw a increase in short interest in June. As of June 30th, there was short interest totaling 436,000 shares, an increase of 38.9% from the June 15th total of 313,900 shares. Based on an average daily trading volume, of 71,800 shares, the short-interest ratio is presently 6.1 days. Approximately 4.5% of the shares of the company are short sold.
View Heska's Short Interest

When is Heska's next earnings date?

Heska is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Heska

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) released its quarterly earnings data on Tuesday, August, 3rd. The medical research company reported ($0.06) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.13. The medical research company had revenue of $64.93 million for the quarter, compared to the consensus estimate of $56.82 million. Heska had a positive trailing twelve-month return on equity of 0.77% and a negative net margin of 3.19%. The business's revenue for the quarter was up 42.0% compared to the same quarter last year.
View Heska's earnings history

How has Heska's stock been impacted by Coronavirus (COVID-19)?

Heska's stock was trading at $81.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HSKA stock has increased by 220.6% and is now trading at $262.33.
View which stocks have been most impacted by COVID-19

What guidance has Heska issued on next quarter's earnings?

Heska issued an update on its FY 2021 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $250 million-$260 million, compared to the consensus revenue estimate of $245.24 million.

What price target have analysts set for HSKA?

5 brokerages have issued 12-month price objectives for Heska's stock. Their forecasts range from $195.00 to $305.00. On average, they expect Heska's share price to reach $249.00 in the next twelve months. This suggests that the stock has a possible downside of 5.1%.
View analysts' price targets for Heska
or view top-rated stocks among Wall Street analysts.

Who are Heska's key executives?

Heska's management team includes the following people:
  • Mr. Kevin S. Wilson, CEO, Pres & Director (Age 49, Pay $1.11M)
  • Ms. Catherine I. Grassman CPA, Exec. VP & CFO (Age 45, Pay $544.53k)
  • Dr. Nancy Wisnewski, Exec. VP & COO (Age 58, Pay $474.3k)
  • Mr. Steven M. Eyl, Exec. VP, Chief Commercial Officer & Pres of scil animal care company (Age 55, Pay $521.34k)
  • Ms. Eleanor F. Baker, Exec. VP, MD & COO of scil animal care company
  • Mr. Christopher D. Sveen, EVP, Chief Admn. Officer, Gen. Counsel, Corp. Sec. & Pres of Diamond Animal Health
  • Mr. Jon Aagaard, Director of Investor Relations
  • Mr. Jason D. Aroesty, Exec. VP of Global Sales and Marketing (Age 45)
  • Daniel J. Pollack, VP of Imaging Operations, Treasurer & Assistant Sec.
  • Laurie E. Peterson, VP of Heska Des Moines

What is Kevin S. Wilson's approval rating as Heska's CEO?

5 employees have rated Heska CEO Kevin S. Wilson on Kevin S. Wilson has an approval rating of 57% among Heska's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Heska's key competitors?

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Who are Heska's major shareholders?

Heska's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Handelsbanken Fonder AB (1.27%), Manning & Napier Group LLC (0.75%), Russell Investments Group Ltd. (0.66%), Monarch Partners Asset Management LLC (0.15%), Alliancebernstein L.P. (0.13%) and Anderson Hoagland & Co. (0.12%). Company insiders that own Heska stock include Bonnie J Trowbridge, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends for Heska

Which major investors are selling Heska stock?

HSKA stock was sold by a variety of institutional investors in the last quarter, including Monarch Partners Asset Management LLC, Russell Investments Group Ltd., Manning & Napier Group LLC, Victory Capital Management Inc., Hillsdale Investment Management Inc., Harel Insurance Investments & Financial Services Ltd., Arizona State Retirement System, and Oppenheimer Asset Management Inc.. Company insiders that have sold Heska company stock in the last year include Bonnie J Trowbridge, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski, and Sharon J Larson.
View insider buying and selling activity for Heska
or view top insider-selling stocks.

Which major investors are buying Heska stock?

HSKA stock was acquired by a variety of institutional investors in the last quarter, including Anderson Hoagland & Co., Alliancebernstein L.P., Handelsbanken Fonder AB, New York State Common Retirement Fund, Waratah Capital Advisors Ltd., Advisor Group Holdings Inc., Cornerstone Investment Partners LLC, and State of Alaska Department of Revenue.
View insider buying and selling activity for Heska
or or view top insider-buying stocks.

How do I buy shares of Heska?

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $262.33.

How much money does Heska make?

Heska has a market capitalization of $2.74 billion and generates $197.32 million in revenue each year. The medical research company earns $-14,400,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How many employees does Heska have?

Heska employs 602 workers across the globe.

What is Heska's official website?

The official website for Heska is

Where are Heska's headquarters?

Heska is headquartered at 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.